|
|
|
|
| LEADER |
05180nam a2200613 4500 |
| 001 |
ocn948604239 |
| 003 |
OCoLC |
| 005 |
20180501122030.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
160503s2016 mau o 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d IDEBK
|d OPELS
|d N$T
|d CDX
|d OCLCF
|d EBLCP
|d YDXCP
|d OCLCQ
|d GrThAP
|
| 019 |
|
|
|a 948826549
|a 949883453
|
| 020 |
|
|
|a 9780128039403
|q electronic bk.
|
| 020 |
|
|
|a 012803940X
|q electronic bk.
|
| 020 |
|
|
|a 9780128039151
|q print
|
| 020 |
|
|
|a 0128039159
|
| 035 |
|
|
|a (OCoLC)948604239
|z (OCoLC)948826549
|z (OCoLC)949883453
|
| 050 |
|
4 |
|a RC422.D52
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.4/62
|2 23
|
| 049 |
|
|
|a TEFA
|
| 245 |
0 |
0 |
|a Controversies in diabetic neuropathy /
|c edited by Nigel A. Calcutt and Paul Femyhough.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press is an imprint of Elsevier,
|c 2016.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 127
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed May 9, 2016).
|
| 505 |
0 |
|
|a Front Cover; Controversies In Diabetic Neuropathy; Copyright; Contents; Contributors; Preface; Section I: Clinical Context; Chapter One: A Brief Introduction to the History and Controversies of Clinical Trials in Diabetic Neuropathy; References; Chapter Two: Neuropathy in the DCCT/EDIC-What Was Done Then and What We Would Do Better Now; 1. Introduction; 2. Neuropathy Outcomes Assessments; 2.1. DCCT and EDIC Design; 2.1.1. Assessment of DSPN in DCCT; 2.1.2. Assessment of DSPN in EDIC; 2.1.3. Additional DSPN Measures in EDIC; 2.1.4. Assessment of CAN in DCCT; 2.1.5. Assessment of CAN in EDIC
|
| 505 |
8 |
|
|a 3. Complementary Assessments in EDIC3.1. Evaluation of Urologic Complications; 3.2. Gastroparesis; 3.3. Other Evaluations in EDIC; 4. DCCT/EDIC Findings; 4.1. DSPN and CAN Outcomes in the DCCT and EDIC Study; 5. Discussion; 5.1. DCCT/EDIC and Contemporary Neuropathy Trials Design; References; Chapter Three: The Perfect Clinical Trial; 1. Introduction; 2. Study Aims: Prevent DSP, Prevent Progression, or Reverse DSP?; 3. Selection of Study Participants; 4. Trial Duration; 5. Study End Points; 6. Core Labs and Training; 7. Intervention; 8. Study Conduct
|
| 505 |
8 |
|
|a 9. Streamlined Ethics and Contracts Process10. Summary; References; Section II: New Models of Diabetic Neuropathy; Chapter Four: An Introduction to the History and Controversies of Animal Models of Diabetic Neuropathy; 1. Why Use Animal Models?; 2. What Species?; 3. What Diabetogenic Insult?; 4. STZ Toxicity; 5. Novel Models; References; Chapter Five: Can Diabetic Neuropathy Be Modeled In Vitro?; 1. Introduction; 2. Diabetic Neuropathy; 3. The Somatosensory Nervous System; 4. Can We Model Diabetic Neuropathy In Vitro?; 4.1. Choice of Cells; 4.1.1. Immortalized Cell Lines
|
| 505 |
8 |
|
|a 4.1.2. Primary Tissue Culture4.1.3. Induced Pluripotent Stem Cells; 4.2. Choice of Stimuli; 4.3. Choice of Output Measure; 4.3.1. Life or Death?; 4.3.2. Altered Bioenergetics and Oxidative Stress; 4.3.3. Neuronal Hyperexcitability; 4.3.4. Axonal Degeneration and Regeneration; 4.4. Looking Forward to a Better In Vitro Model of Diabetic Neuropathy; 5. Conclusions; Acknowledgments; References; Chapter Six: Alternatives to the Streptozotocin-Diabetic Rodent; 1. Introduction; 2. Rodent Models of Obesity; 2.1. High-Fat Fed Sprague-Dawley Rats and C57Bl6/J Mice; 2.2. Zucker Rats
|
| 505 |
8 |
|
|a 3. Rodent Models of Type 2 Diabetes3.1. Zucker Diabetic Fatty Rats; 3.2. Spontaneously Diabetic Torii Rat; 3.3. Zucker Diabetic Sprague-Dawley Rat; 3.4. Goto-Kakizaki Rat; 3.5. BioBreeding Zucker Diabetic Rat; 3.6. Otsuka Long-Evans Tokushima Fatty Rat; 3.7. Ob/ob and db/db Mice; 3.8. Tsumura Suzuki Obese Diabetes Mouse; 3.9. Combined High-Fat Fed, Low-Dose Streptozotocin Models of Type 2 Diabetes; 3.10. Streptozotocin-Nicotinamide Rat; 4. Rodent Models of Type 1 Diabetes; 4.1. Spontaneously Hypertensive Rat; 4.2. BioBreeding/Worcester Rat; 4.3. Ins2Akita Mouse; 4.4. Nonobese Diabetic Mouse
|
| 650 |
|
0 |
|a Diabetic neuropathies.
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a Diabetic neuropathies.
|2 fast
|0 (OCoLC)fst00892230
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Calcutt, Nigel A.,
|e editor.
|
| 700 |
1 |
|
|a Fernyhough, Paul,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|a Calcutt, Nigel
|t Controversies In Diabetic Neuropathy
|d : Elsevier Science,c2016
|z 9780128039151
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 127.
|
| 856 |
4 |
0 |
|u https://www.sciencedirect.com/science/bookseries/00747742/127
|z Full Text via HEAL-Link
|
